ID: ALA2413690

Max Phase: Preclinical

Molecular Formula: C18H19BrN2O5S

Molecular Weight: 455.33

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCN(CC)S(=O)(=O)c1cccc(C(=O)Nc2ccc(Br)cc2C(=O)O)c1

Standard InChI:  InChI=1S/C18H19BrN2O5S/c1-3-21(4-2)27(25,26)14-7-5-6-12(10-14)17(22)20-16-9-8-13(19)11-15(16)18(23)24/h5-11H,3-4H2,1-2H3,(H,20,22)(H,23,24)

Standard InChI Key:  NFJLRAOTHHGGDY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 455.33

Molecular Weight (Monoisotopic): 454.0198

AlogP: 3.43

#Rotatable Bonds: 7

Polar Surface Area: 103.78

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.40

CX Basic pKa:

CX LogP: 3.91

CX LogD: 0.51

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.67

Np Likeness Score: -1.90

References

1. Weidel E, de Jong JC, Brengel C, Storz MP, Braunshausen A, Negri M, Plaza A, Steinbach A, Müller R, Hartmann RW..  (2013)  Structure optimization of 2-benzamidobenzoic acids as PqsD inhibitors for Pseudomonas aeruginosa infections and elucidation of binding mode by SPR, STD NMR, and molecular docking.,  56  (15): [PMID:23834469] [10.1021/jm4006302]

2. Hinsberger S, de Jong JC, Groh M, Haupenthal J, Hartmann RW..  (2014)  Benzamidobenzoic acids as potent PqsD inhibitors for the treatment of Pseudomonas aeruginosa infections.,  76  [PMID:24589489] [10.1016/j.ejmech.2014.02.014]

Source

Source(1):

• Scientific Literature